IRVINE, Calif., May 9, 2013 /PRNewswire via COMTEX/ -- AtheroNova Inc. (OTN:AHRO) , a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today ...

AtheroNova Inc. (otcqb:AHRO) is taking a new approach in treating atherosclerotic plaque that doesn't involve simply targeting LDL cholesterol levels.

WG: AtheroNova Inc. (AHRO:OTCQB) is developing therapies based on naturally occurring bile salts, which are produced in the body and used in the digestive tract to dissolve or emulsify lipids.

IRVINE, Calif., April 15, 2013 /PRNewswire via COMTEX/ -- AtheroNova Inc. (OTN:AHRO) , a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today ...

... and SATURN studies has put forth not only questions of the effectiveness of statins, but suggested that statins may have a negative effect overall as discussed in a research report by Crystal Research Associates, LLC on AtheroNova Inc. (OTCQB: AHRO).

Dodd has been involved in the sale of Stem Cell Sciences and Serologicals Corporation and is currently the CEO of RiversEdge BioVentures, which he founded.